Lu-Ann Murdoch
ARTICLES BY THIS AUTHOR
- 8/21/2023
First update to the rheumatoid arthritis ‘living guidelines’ is now available
Canadian Rheumatology Association issues best practice statements and recommendation for choosing DMARD therapy after an inadequate response to TNF inhibitors. - 8/17/2023
Is it GERD or typical spit up? PPI use in young children may increase risk of serious infections
Proton pump inhibitors (PPIs) should not be used without a clear indication in the pediatric population. - 8/14/2023
Diabetes Canada issues position statement on do-it-yourself automated insulin delivery
Healthcare providers should discuss all available treatment options that have evidence of benefit with individuals living with type 1 diabetes, including DIY options. - 8/10/2023
POP QUIZ: Dyslipidemia in children
In 2022, the Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association published clinical practice guidelines for the management of dyslipidemia in children and adolescents. - 8/9/2023
Canada, U.S. consensus guidelines for the management of acetaminophen poisoning
New guidelines have evidence-based recommendations for medical, pharmacy and nursing staff to optimize care of patients with acetaminophen poisoning. - 8/8/2023
SGLT2 inhibitors may reduce recurrent gout flares in type 2 diabetes patients
Sodium–glucose cotransporter-2 inhibitors may also reduce gout-related emergency department visits and hospitalizations, as well as provide cardiovascular benefits. - 8/3/2023
Health Canada is reviewing two Omicron XBB.1.5-based COVID-19 vaccines
XBB.1.5-based monovalent vaccines from Pfizer and Moderna are undergoing expedited review by Health Canada. - 7/31/2023
Do mRNA COVID-19 vaccines cause heavy menstrual bleeding?
A Health Canada safety brief examines the link between vaccination with Pfizer’s Comirnaty or Moderna’s Spikevax and the risk of heavy menstrual bleeding. - 7/30/2023
Daily low-dose ASA increases intracranial bleeding risk by 38% in healthy older adults
Low-dose ASA should not be routinely prescribed for the primary prevention of stroke, particularly in older persons predisposed to head trauma from falls. - 7/24/2023
Be aware of possibility of acute uveitis after IV zoledronate for osteoporosis
Ocular pain, blurred vision, photosensitivity, hyperemia and other ocular symptoms may begin two to four days after the bisphosphonate infusion.
